A Phase I/Ii Study Of Enadenotucirev, A Chimeric Ad11/Ad3 Oncolytic Group B Adenovirus, Administered Intraperitoneally (Ip) In Platinum-Resistant Epithelial Ovarian Cancer: Pharmacokinetic (Pk) And Tolerability Data From Phase I
JOURNAL OF CLINICAL ONCOLOGY（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要